BRIEF-AstraZeneca's MedImmune, NGM Biopharmaceuticals in deal to develop therapies for diabetes and obesity

LONDON, June 17 Mon Jun 17, 2013 3:20am EDT

LONDON, June 17 (Reuters) - AstraZeneca PLC : * Medimmune,NGM Biopharmaceuticals announce agreement to discover and develop

therapies for diabetes and obesity * MedImmune,NGM will jointly advance peptide and antibody drug candidates based

on discovered eec hormones * MedImmune will be responsible for global development,

manufacture,commercialisation of compounds from collaboration

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.